Cargando…
CML patients in the molecular era – report of five years experience of diagnosis and treatment in a single center
Chronic myeloid leukemia (CML) represents about 15% of all leukemia cases. Although the incidence of the disease is rather low, the therapeutic progress of the last decade has dramatically changed the evolution of this disease, whose survival considerably increased and in whom we now speak even abou...
Autores principales: | Voican, I, Vladareanu, AM, Bumbea, H, Barsan, L, Vasile, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786495/ https://www.ncbi.nlm.nih.gov/pubmed/24146695 |
Ejemplares similares
-
Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors. The first molecular targeted treatment
por: Bumbea, H, et al.
Publicado: (2010) -
Splenectomy in Lymphoproliferative Disorders: A Single Eastern European Center Experience
por: Onisâi, Minodora, et al.
Publicado: (2019) -
Correlations of hematological parameters with bone marrow findings in chronic lymphoproliferative disorders associated with hepatitis viruses
por: Ciufu, C, et al.
Publicado: (2013) -
A Challenging Case of Kikuchi-Fujimoto Disease Associated with Systemic Lupus Erythematosus and Review of the Literature
por: Găman, Mihaela, et al.
Publicado: (2018) -
Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms
por: Vladareanu, AM, et al.
Publicado: (2011)